CommercialCoverageMedium impact
08.01.48c, Tildrakizumab-asmn (Ilumya®)
Independence Blue Cross·Dermatology, Rheumatology·Pharmacy
Effective date
Sep 14, 2026
We identified it
Jun 19, 2026
Summary
Policy 08.01.48c for Tildrakizumab-asmn (Ilumya®) has been updated with changes to coverage position, medical necessity criteria, and medical coding requirements. This affects billing for this specialty psoriasis medication with new requirements taking effect September 14, 2026.
Action Required
By September 14, 2026: Billing team must review and implement updated medical necessity criteria and coding requirements for Tildrakizumab-asmn (Ilumya®). Update prior authorization workflows and documentation requirements in billing system. Notify providers of new coverage criteria to ensure compliance before effective date.